| __timestamp | ADMA Biologics, Inc. | Axsome Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 1392830 |
| Thursday, January 1, 2015 | 6745968 | 2419289 |
| Friday, January 1, 2016 | 8494742 | 6343648 |
| Sunday, January 1, 2017 | 18092835 | 7206691 |
| Monday, January 1, 2018 | 22502922 | 9351522 |
| Tuesday, January 1, 2019 | 25910757 | 13598030 |
| Wednesday, January 1, 2020 | 35050817 | 28896749 |
| Friday, January 1, 2021 | 42896889 | 66646205 |
| Saturday, January 1, 2022 | 52458024 | 159253661 |
| Sunday, January 1, 2023 | 59020000 | 323123000 |
| Monday, January 1, 2024 | 411359000 |
Data in motion
In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Axsome Therapeutics, Inc. and ADMA Biologics, Inc. from 2014 to 2023. Over this period, Axsome Therapeutics has seen a staggering increase in SG&A expenses, growing by over 23,000% from 2014 to 2023. In contrast, ADMA Biologics experienced a more modest rise of approximately 1,100% during the same timeframe. This divergence highlights the different growth trajectories and strategic priorities of these two companies. Axsome's rapid expansion in expenses could indicate aggressive scaling and investment in infrastructure, while ADMA's steadier increase suggests a more conservative approach. Understanding these trends provides valuable insights into the operational strategies of biotech firms and their impact on financial health.
Selling, General, and Administrative Costs: Pfizer Inc. vs Axsome Therapeutics, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Axsome Therapeutics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?
ADMA Biologics, Inc. or ACADIA Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ADMA Biologics, Inc. and Mesoblast Limited